Artículo 24 Oct 2019

How Brazil’s pharma industry faces new challenges

An infusion that saves the lives of patients suffering from a rare disease, an electronic cigarette, a child nutrition formula, hair straighteners, insecticides for crops and household sanitizers… There is a universe of products our bodies absorb in a wide variety of ways, and all are subject to more stringent regulations than other kinds of products. In most of the Western world, these regulations establish how an item is labeled, applied, packaged, sold, distributed and promoted… if the product in question is even allowed. In Brazil, the agencies, foundations and offices in charge of these regulations are housed within the Ministry of Health.

Despite the limitations regulatory agencies have imposed over the past five years -between the periods 2014/2015 and 2019/2020- we have seen how associations have become empowered, helped by the ubiquitous involvement of macro- and micro-influencers, as well as the inescapable world of social media. Thinking of political mobilization through the lens of social media was a novelty in 2011, when the Arab Spring changed North Africa’s status quo by organizing gatherings via Twitter.

A new setting

In this context, sharing economy companies like Uber and Airbnb have paved the way for the use of big data to acquire in-depth knowledge of and influence in and through their communities of interest. In turn, there is another sector—both traditional and innovative—exploring a road that, through advocacy actions, leads to a common and essential goal: Social license to operate.

After observing the Brazilian scenario and facing the growing demand for grassroots action, we have noticed a higher success rate in the pharmaceutical industry than other sectors. Positive regulatory response, even with restrictions, is considered essential for this success.

If volatility, uncertainty, complexity and ambiguity are features of a world where success, or even the sole existence of a business increasingly depends on communication, aka the ability to engage, what challenges is the pharmaceutical industry successfully addressing that could serve as a benchmark for other sectors?

“The pharmaceutical industry is exploring a path that, through advocacy actions, leads to the most essential and common goal: obtaining its social license to operate”

Challenge 1: listening to and understanding communities

The first challenge for evolution arises from government and law-maker responses to the use of personal information obtained by apps and tools that gather, store and resend big data.

Apart from the legal aspect, which still forms the basis of discussions on how to enforce regulations in practice, these laws are a symptom of a broader awareness across different sectors of society regarding the collection and use of personal data for political or commercial purposes. There have already been signs of people rejecting certain social media and brands.

Challenge 2: protagonism

This response by the industry leads to the second challenge: Protagonism. Traditional grassroots campaigns or pre-Brexit political campaigns always engineered digital campaigns for a candidate or corporation with a clear selfish interest (winning an election or making profit), even though they could also result in potential benefits for the community.

In the case of the 2018 election campaign in Brazil, this was reflected by statements claiming “I am Bolsonaro’s caixa 2” on T-shirts or signs voters made to support their candidate. Sending political information over WhatsApp, was successful precisely thanks to the feeling of closeness with the supposed sender, who forwarded it to their direct contacts on a shared social network.

Thus, in the analyzed Brazilian cases, the solution adopted by the pharmaceutical industry by way of advocacy is far more sustainable.

Challenge 3: fake news

More than acting as a campaign catalyst or spokesperson, playing an educational role allowed the analyzed pharmaceutical companies to overcome the third challenge looming in today’s world: Fake news.

One example of the harm fake news has caused, both in society and among corporations, is the flare-up of diseases that appeared to be under control. A good example of this is the currently worsening measles outbreak and damage caused to vaccine companies as a result of the anti-vaxxer movement.

Part of the reluctance is the difficulty of finding a prominent figure or training specialists outside their sphere of direct influence, or that of the government’s. This highlights how disruptive it is for this sector—just like for most corporations—to follow the path of joining vertical knowledge and horizontal communication.

“Playing an educational role allowed the analyzed pharmaceutical companies to overcome the third challenge looming in today’s world: Fake news”

A disruptive path by nature

At the end of the day, we are all part of this scenario, alternately playing the roles of subject and object.

For the companies and sectors that choose to pave the way and contribute to the storylines that will have an impact on their businesses, this road’s nature is per se disruptive. This means there will be new challenges lying ahead, for which we must find new solutions.

On the other hand, it also means the lessons learned about the importance of being transparent, investing in information and giving up the spotlight are part of a legacy that may lead us safely into the future.

Thyago Mathias
Senior Director of Advocacy and Strategic Communications at LLYC in Brazil
With degrees in Journalism and Law, Thyago has over 15 years of experience in both public sector – in the State Congress of Rio de Janeiro and as an advisor in projects for the Federal government through the Fundação Getúlio Vargas (FGV) – and private sector, having worked with the largest media companies in Brazil, such as UOL and TV Globo, for which he was a correspondent in Egypt (G1 web portal), and content supervisor of Globo Universidade. With a specialization in International Relations and an MBA in Project Management from the FGV, Thyago has participated in the opening of the LLYC office in São Paulo, where he has developed advocacy projects, strategic communication and crisis management and reputation for clients which were already recognized by three Latam Saber Awards, three Latin American Excellence Awards, two Aberje awards and one Jatoba Award.
Tuca Figueira
Healthcare Communications and Advocacy Director at LLYC in Brazil
With more than 20 years of experience in strategic and health communications, Tuca Figueira has worked for customers such as Hospital de Santa Catarina, Biogen, Alexion, Department of Metropolitan Transportation of the State of São Paulo, PepsiCo., among others. She is specialized in the pharmaceutical area, providing crisis management and institutional branding services. At S/A LL&C, Tuca works in reputation management projects and support to areas of advocacy and marketing, as well as patient organizations and several industries. Tuca has a degree in Public Relations from Faculdade Cásper Líbero, specialization in Institutional Journalism from PUC/SP, MBA in Corporate Communication Management from FECAP/SP and specialization in Public Policy and Advocacy from PEC FGV/SP.

We want to collaborate with you

Do you have a challenge?

Would you like to join our team?

Do you want us to speak at your next event?